Results 351 to 360 of about 462,118 (388)

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

New England Journal of Medicine, 2000
BACKGROUND Angiotensin-converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure.
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais   +5 more
semanticscholar   +1 more source

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Journal of the American Medical Association (JAMA), 2002
CONTEXT Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. K. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara M. Simpson, J. Blanton, T. Geraci, Sandra M. Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Ann Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. L. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi   +56 more
semanticscholar   +1 more source

Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review

Expert Review of Clinical Pharmacology, 2022
Angiotensin converting enzyme inhibitors (ACEI) are commonly used for cardiovascular diseases. The evidence supporting the use of ACEI in dermatology is limited.This review article was divided into three parts. The first part discusses ACEI in clinical use in dermatology.
Yang, Lo, Tsen-Fang, Tsai
openaire   +2 more sources

Angiotensin-Converting Enzyme in Neurosarcoidosis

Archives of Neurology, 1987
To the Editor. —We read with great interest the article by Sethi et al in the June 1986 issue of theArchives.1We wish to point out another important aspect of neurosarcoidosis that was not discussed by the authors, namely, determination of angiotensin I—converting enzyme (ACE) levels in the cerebrospinal fluid (CSF) of patients with suspected ...
Israel Rubinstein, Victor Hoffstein
openaire   +3 more sources

Angiotensin-converting enzyme inhibitors

Critical Care Nurse, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
BL Herlihy, JT Herlihy
openaire   +5 more sources

The angiotensin converting enzyme in the kidney

Journal of Hypertension, 1989
Immunohistochemical studies and experiments with microdissected nephron segments indicate that the angiotensin I converting enzyme (ACE) in the kidney is expressed in the vascular endothelial cells of the renal vessels and in the epithelial cells of the proximal convoluted tubule and the pars recta.
Florent Soubrier, T. Baussant, Christine Hubert, François Alhenc-Gelas, Pierre Corvol   +4 more
openaire   +3 more sources

angiotensin converting enzyme inhibitors

2012
More than 30 years since their discovery, angiotensin-converting enzyme (ACE) inhibitors still represent one of the most commonly prescribed medications for treating hypertension and one of the favored first-line agents, particularly in the presence of high-risk conditions, such as diabetes.
GENTILE, GIORGIO, REBOLDI, Gianpaolo, ANGELI, FABIO, G. Mazzotta, P. Verdecchia   +4 more
openaire   +4 more sources

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Journal of the American Medical Association (JAMA), 2020
Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The particularly infectious capacity of the virus, along with mortality rates
A. Patel, A. Verma
semanticscholar   +1 more source

The angiotensin converting enzyme (ACE)

The International Journal of Biochemistry & Cell Biology, 2003
Angiotensin converting enzyme 1, found widely throughout the animal kingdom, is an integral membrane bound protein whose active sites are directed to the extracellular spaces. Two isoforms are expressed in mammals, a single domain germinal isoform required for male fertility, and a double domain somatic isoform which has a key role in the renin ...
openaire   +3 more sources

Angiotensin converting enzyme inhibitors

Pharmaceutisch Weekblad Scientific Edition, 1982
Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described.
openaire   +2 more sources